Tokyo,Japan June 5, 2024  Craif, a molecular diagnostic company that has developed a miRNA based early cancer detection platform, is proud to announce its selection as one of the 65 companies accepted into the prestigious 2024 Medtech Innovator Accelerator Cohort, the world's largest medical technology accelerator. Craif was chosen from approximately 1,300 companies worldwide.

　The MTI accelerator program identifies startups in medical devices, diagnostics and digital health with innovative medical technologies and provides them with four months of support from leading industry partners and experts. MTI’s  mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. Among the approximately 600 graduated companies, there have been 310 medical devices, diagnostics and digital health platforms, who have received  U.S. regulatory approval and are being used in clinical settings.

　“Craif will leverage the accelerator to support the development in the US of our  early pancreatic cancer detection assay.  Our miRNA platform has been shown to have high predictive ability across a number of different types of cancer.   We have chosen to focus on pancreatic cancer in high risk patients because of the diagnostic dilemma.  Pancreatic cancer is only treatable in early stages and the current standard of care (imaging) is missing many early stage cancers (< 2 cm) resulting in poor outcomes.  Our diagnostic could help improve outcomes by finding more patients with early stage pancreatic cancer resulting in more patients being sent to curative treatment”  said CEO and Co-Founder Ryuichi Onose.  

For more information, visit MedTech Innovator’s website.